You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)2020年淨利同比增加38.9%至51.60億元 末期息每股9港仙
格隆匯 03-15 16:52

格隆匯 3 月 15日丨石藥集團(01093.HK)公吿,於截至2020年12月31日止年度,集團收入增加12.8%至人民幣249.42億元,股東應占溢利增加38.9%至人民幣51.60億元,每股基盈利相應增加至人民幣43.16分。董事會建議派發2020年末期股息每股9港仙。

集團憑藉其強大的專業化市場開拓能力、完備的管理體系、優秀的企業文化和持續的創新研發能力,已成為行業的頭部企業,並向行業標杆邁進。

2020年,席捲全球的新冠疫情為人類健康和世界經濟都蒙上了陰影,中國醫藥行業的發展面臨前所未有的挑戰。集團迎難而上,在艱難的環境下創造了亮麗的業績增長。創新藥產品繼續保持高速增長,恩必普、多美素、津優力、克艾力等重磅品種再次創造了驕人的銷售成績。恩必普累計開展的超過150項醫學研究,為市場下沉、持續成長提供了強大支持。恩必普年內順利通過了醫保支付標準的談判,產品價格降低後,可及性和可負擔性顯著提高。隨着市場進一步下沉和線上銷售,將惠及更多患者,帶動銷量增長。

抗腫瘤藥品持續拓展市場準入,加大學術推廣投入,擴大專業的銷售隊伍,大幅提升了目標醫院的覆蓋率。克艾力以最低價在第二輪國家集採中中標,併成功進入國家醫保目錄,將大大促進產品渠道下沉、加速放量。普藥產品方面,集採中標恩存(硫酸氫氯吡格雷片)迅速打開醫院市場,成為新的增長點,體現了集團普藥產品的規模化、系列化發展優勢。達新寧(鹽酸決奈達隆片)、舒安靈(己酮可可鹼注射液╱片)及恩悉(鹽酸普拉克索片)等新上市品種銷售增長迅速,亦為集團的增長添加了新動力。第四批集採中以合理價格中標的艾司奧美拉唑鎂腸溶膠囊、布洛芬片、鹽酸度洛西汀腸溶膠囊、注射用硼替佐米、鹽酸普拉克索片和諾氟沙星片,將迅速進入醫院終端,又將增加新的利潤增長源。

2020年開發的臨牀產品和適應症均取得了理想進展。自年初至今共有17個產品獲得藥品註冊批件,14個產品獲得臨牀試驗批件,24個品種通過了仿製藥一致性評價。

重磅產品創新制劑鹽酸米託蒽醌脂質體注射液的上市申請獲得優先審評,並已通過生產現場檢查及臨牀試驗核查;創新藥Duvelisib在中國的橋接試驗完成病例入組,已提交上市申請;兩性黴素B脂質體已提交上市申請,伊立替康脂質體的臨牀試驗進展順利,預計於近期提交上市申請。過往三年,集團在研發方面持續加大投入,研發費用複合增長率達到46.7%。

研發管線持續豐富的同時,臨牀研究的實驗進度大幅加快,試驗患者入組成倍增長,出現了大量極好的臨牀試驗數據。隨着研發費用投入的持續增加,相信研發管線佈局的產品和治療適應症將會更豐富多樣,已拓展的幾個大治療領域的幾十個新適應症中,近三年會有多個新藥獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account